HACKENSACK, N.J.--(BUSINESS WIRE)--Amorcyte, Inc. (Amorcyte), a privately funded biotechnology company developing cell therapy products to treat cardiovascular disease, has secured additional funding to complete its first Phase I trial and pursue additional cell therapy opportunities for cardiac and vascular diseases.
